2025.05.31 (토)

  • 구름많음동두천 17.6℃
  • 맑음강릉 20.3℃
  • 구름많음서울 18.2℃
  • 맑음대전 18.5℃
  • 맑음대구 19.0℃
  • 맑음울산 20.0℃
  • 맑음광주 18.4℃
  • 맑음부산 19.1℃
  • 맑음고창 18.4℃
  • 맑음제주 21.3℃
  • 구름많음강화 15.3℃
  • 구름조금보은 17.3℃
  • 맑음금산 18.1℃
  • 맑음강진군 18.7℃
  • 구름조금경주시 20.7℃
  • 맑음거제 19.7℃
기상청 제공
닫기

English

Finance also supports the growth of Korea's aerospace and defense industry... KB Kookmin Bank and KAI join hands for 1 trillion won of mutually beneficial cooperation

 

[News Space=Reporter seungwon lee] On the 11th, Kookmin Bank (CEO Hwan-Joo Lee) signed a business agreement for ‘mutual cooperation and joint development’ with KAI (Korea Aerospace Industries, Ltd., CEO Gu-Young Kang).

 

The signing ceremony held at the new building of KB Kookmin Bank in Yeongdeungpo-gu, Seoul was attended by KAI President Kang Gu-young, KB Kookmin Bank President Lee Hwan-joo, and officials from both organizations.

 

This agreement was prepared to strengthen competitiveness in the aerospace sector, a key national industry, support entry into the global market, and establish a mutual cooperation system between the two organizations.

 

According to this agreement, the financial support that Kookmin Bank will provide to KAI is up to KRW 1 trillion. It will provide financial solutions for projects conducted by KAI, such as ▲Future business investment support ▲Export finance ▲Loans for operating funds related to exports, imports, and facility investments. In addition, it plans to practice win-win finance with small and medium-sized enterprises through financial support for joint growth targeting KAI's partner companies.

 

KAI President Kang Gu-young said, “Since the aerospace industry is a field that requires high technological prowess and long-term investment, stable financial support is very important,” and “We expect that this agreement will further strengthen the foundation for future business investment and global market expansion.”

 

Lee Hwan-joo, President of Kookmin Bank, said, “I am deeply honored to have signed an agreement with KAI, which has been leading the aerospace and defense industry in Korea,” and added, “I hope that this will become a cornerstone for going beyond simple financial support to enhance the competitiveness of Korea’s aerospace industry and achieve sustainable growth together.”

이승원 기자의 전체기사 보기

저작권자 © 뉴스스페이스(NewsSpace) 무단전재 및 재배포 금지

배너
배너
배너

관련기사

93건의 관련기사 더보기

이 시각 추천뉴스

Human division 'Samsung Bio' catches three rabbits... Bio global super gap, strengthening of Lee Jae-yong's control, asset value reevaluation 'a stroke of genius'

[News Space=Reporter seungwon lee] Samsung BioLogics is drastically reorganizing its business structure through a spin-off. On the 22nd, Samsung BioLogics announced through a public disclosure that it will split the company into the surviving corporation, ‘Samsung BioLogics’, which will be in charge of the contract development and manufacturing organization (CDMO) business, and the newly established corporation, ‘Samsung Epi Holdings’, which will act as an investment and holding company for biosimilar and new drug development. This split is a strategic decision to strengthen the expertise and

Lee Hae-jin, who went to Taiwan, met Jensen Huang, and the ‘AI alliance’ began in earnest… Naver and Nvidia ‘discuss’ cooperation on Sovereign AI

[News Space=Reporter seungwon lee] Naver Chairman Lee Hae-jin met with NVIDIA CEO Jensen Huang in Taiwan and signaled a new phase in the global AI leadership competition. This meeting was held during Asia's largest IT exhibition, 'Computex 2025', and NVIDIA's cloud partner event, 'NPC Summit', and the discussion on 'Sovereign AI' cooperation, which combines Naver's AI strategy and NVIDIA's infrastructure, emerged as a key agenda. Naver executives mobilize to attack Southeast Asia AI market in earnest Chairman Lee Hae-jin visited Taiwan with key executives, including Naver CEO Choi Soo-yeon and

Osstem Pharma participates in China Beauty Expo… Viewsen fever ‘hot’, global strategy ‘accelerates’

[News Space=Reporter seungwon lee] Osstem Pharma (CEO Moon Byeong-jeom), a subsidiary of Osstem Implant, announced that it received enthusiastic interest and response by introducing an exhibition booth for its premium oral care brand 'Viewsen' at the 'China Beauty Expo 2025 (CBE)' held at the Shanghai International Expo Center from May 12 to 14. CBE is the largest beauty trade show in Asia. This year, in its 29th year, over 3,500 companies from 80 countries around the world opened booths and attracted over 500,000 visitors. Osstem Pharma set up a brand promotion booth centered around the Views

Novartis, Profitability Regresses Despite Sales Increase… Net Income Approaching Dividends, Patent Infringement Lawsuits, Cash Assets 0 Won 'Risk'

[News Space=Reporter seungwon lee] Despite the increase in sales in 2024, Novartis Korea (CEO Yoo Byung-jae) saw its profitability decline as both operating profit and net profit decreased. The operating profit ratio also fell to 3.7%. In addition, short-term borrowings increased and cash assets remain at 0 won, making liquidity management weak. The scale of purchases and debts with special related parties (head office, etc.) is large, and the financial structure has improved somewhat due to inventory asset reduction and restructuring (dramatic reduction in retirement benefits), but the group

Celltrion Signs Contract with Large US PBM for 'Stekima' Listing… Full-scale Expansion of Reimbursement Coverage

[News Space=Reporter seungwon lee] Celltrion has successfully expanded its coverage by signing a formulary listing contract for its autoimmune disease treatment drug 'Steqeyma' (ingredient name: ustekinumab) with one of the top five prescription drug benefit managers (PBM) in the United States. As Celltrion secures the private insurance area under the jurisdiction of the PBM through this contract, Stekima is scheduled to receive a refund starting July 1. This contract is the second achievement that Celltrion has made with a large US PBM for the listing of Stekima in the formulary. Prior to thi

Daewon Pharmaceutical Risk (Part 4): From ‘Domestic New Drug Myth’ to ‘Bad Company’ Stigma… 4 Consecutive Patent Losses, Quality Risk, and the ‘Bare Face’ of Family Management

[News Space=Reporter seungwon lee] Daewon Pharmaceutical, once the pride of domestic new drugs, has lost four consecutive patent lawsuits for ‘Pelubi’ from the first trial to the Supreme Court, exposing its management incompetence and structural risks at once. In recent years, Daewon Pharmaceutical has been criticized as a typical ‘bad company’ due to repeated investigations by the Ministry of Food and Drug Safety and the National Tax Service, as well as repeated defeats in court. ◆ Four consecutive patent lawsuit losses… The fall of the Pelubi myth Daewon Pharmaceutical’s domestic new drug ‘P

“Risk to subcontractor, profit to general contractor” Hyundai-Kia industrial accidents reveal their true colors… ‘Conveyor belt of death’ is ongoing

[News Space=Reporter seungwon lee] The symbol of Korean manufacturing: Hyundai and Kia Motors factories. The workers there are called “new production workers” with hundreds of millions of won in annual salaries, but behind the splendid facade, there are industrial accidents, occupational diseases, and the tears of subcontracted workers. Even more shocking is the tyranny of Hyundai and Kia Motors, which evades all responsibility with their powerful power and capital. Over the past five years, more than 2,061 people were injured, and 28 people lost their lives… “Passing responsibility to subcont

28 dead, 2,000 injured in 5 years… Hyundai-Kia’s ‘real face of industrial accidents’ hidden behind billion-dollar salaries

[News Space=Reporter seungwon lee] Another worker death accident has occurred at Hyundai Motor Company and Kia Motors plants. Following the accident at Kia's Gwangju plant on May 16 in which a worker in his 40s was caught in a machine transporting a finished vehicle and died, the two companies' plants have been experiencing a series of serious accidents in recent years, including entrapment, falls, and suffocation. Although it is a job that boasts an annual salary in the hundreds of millions, to the point that it is called a 'new production job,' it is pointed out that backward and repetitive

Daewon Pharmaceutical Risk (Part 3): Domestic New Drug 'Pelubi' Patent Loss for 4th Consecutive Time, Closing Growth Plate... Corporate Crisis Revealing Absence of Strategy and Incompetence of Management 'Negative Lesson'

[News Space=Reporter seungwon lee] As Daewon Pharmaceutical lost the patent lawsuit for its representative domestic new drug 'Pelubi' in the first and second trials, as well as in the third trial at the Supreme Court, the lack of strategy and crisis management capabilities of the management were clearly revealed. As this ruling makes it virtually inevitable for the drug price of Peluvi to be lowered, a sales decrease of hundreds of billions of won is expected to become a reality. ◆ Another lawsuit after losing four times?… Key reason for losing four times in a row Daewon Pharmaceutical has los

많이 본 뉴스

더보기